These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. Development of Novel Pharmaceutical Agents for Alzheimer's Disease: The Impact of Regulatory Initiatives in Japan and the United States. Tsukamoto K Clin Ther; 2015 Aug; 37(8):1652-60. PubMed ID: 25801940 [TBL] [Abstract][Full Text] [Related]
10. Beyond immunotherapy: new approaches for disease modifying treatments for early Alzheimer's disease. Ruthirakuhan M; Herrmann N; Suridjan I; Abraham EH; Farber I; Lanctôt KL Expert Opin Pharmacother; 2016 Dec; 17(18):2417-2429. PubMed ID: 27825018 [TBL] [Abstract][Full Text] [Related]
11. In silico repurposing of antipsychotic drugs for Alzheimer's disease. Kumar S; Chowdhury S; Kumar S BMC Neurosci; 2017 Oct; 18(1):76. PubMed ID: 29078760 [TBL] [Abstract][Full Text] [Related]
12. Targeting amyloid precursor protein secretases: Alzheimer's disease and beyond. Ganjei JK Drug News Perspect; 2010 Nov; 23(9):573-84. PubMed ID: 21152452 [TBL] [Abstract][Full Text] [Related]
13. Potential therapeutic agents against Alzheimer's disease from natural sources. Park SY Arch Pharm Res; 2010 Oct; 33(10):1589-609. PubMed ID: 21052936 [TBL] [Abstract][Full Text] [Related]
14. Progress in Alzheimer's disease drug discovery: an update. Williams M Curr Opin Investig Drugs; 2009 Jan; 10(1):23-34. PubMed ID: 19127484 [TBL] [Abstract][Full Text] [Related]
15. Development of biomarkers to chart all Alzheimer's disease stages: the royal road to cutting the therapeutic Gordian Knot. Hampel H; Lista S; Khachaturian ZS Alzheimers Dement; 2012 Jul; 8(4):312-36. PubMed ID: 22748938 [TBL] [Abstract][Full Text] [Related]
16. Inflammatory mediators leading to protein misfolding and uncompetitive/fast off-rate drug therapy for neurodegenerative disorders. Lipton SA; Gu Z; Nakamura T Int Rev Neurobiol; 2007; 82():1-27. PubMed ID: 17678953 [TBL] [Abstract][Full Text] [Related]
17. Current Practices in the Treatment of Alzheimer Disease: Where is the Evidence After the Phase III Trials? Ehret MJ; Chamberlin KW Clin Ther; 2015 Aug; 37(8):1604-16. PubMed ID: 26122885 [TBL] [Abstract][Full Text] [Related]
18. Closing in on the amyloid cascade: recent insights into the cell biology of Alzheimer's disease. Huse JT; Doms RW Mol Neurobiol; 2000; 22(1-3):81-98. PubMed ID: 11414282 [TBL] [Abstract][Full Text] [Related]
19. Alzheimer's therapeutics: continued clinical failures question the validity of the amyloid hypothesis-but what lies beyond? Mullane K; Williams M Biochem Pharmacol; 2013 Feb; 85(3):289-305. PubMed ID: 23178653 [TBL] [Abstract][Full Text] [Related]
20. Alzheimer's disease drug development based on Computer-Aided Drug Design. Zeng H; Wu X Eur J Med Chem; 2016 Oct; 121():851-863. PubMed ID: 26415837 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]